17.08.2022 • NewsKaofragrance

Kao Expands Synthetic Fragrance in Spain

Japan’s Kao Corp. is planning to double capacity of synthetic fragrance methyl dihydrojasmonate (MDJ) at its plant in Spain as it aims to expand market share in Europe for the jasmine-scented product.

Kao, which regards itself as the market leader in the region for MDJ, will complete the expansion at its Olesa plant by December 2022, with the additional output scheduled to be available in early 2023.

The new facility will use unique technology developed by Kao, which said the enhanced productivity will cut CO2 emissions by 2,000 t/y, while also reducing the amount of energy needed for waste water treatment. All saline wastewater – currently amounting to about 850 t/y – will be eliminated.

Demand in Europe – the biggest market for MDJ – has remained steady while global demand is forecast to grow at 4% per year, according to the Tokyo-based group. MDJ is used in a wide range of consumer products because of its good compatibility with other materials. The market was estimated at 20,000 t in 2021.

Author: Elaine Burridge, Freelance Journalist

© Shutterstock/ Artfully Photographer
© Shutterstock/ Artfully Photographer

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.